#nasdaq:uthr

Analyst Activity – Wedbush Reiterates Outperform on United Therapeutics Corporation (NASDAQ:UTHR)

Analyst Ratings For United Therapeutics Corporation (NASDAQ:UTHR) Today, Wedbush reiterated its Outperform rating on United Therapeutics Corporation (NASDAQ:UTHR) with a price target of $229.00. There are 1 sell rating, 6 hold ratings, 5 buy ratings on the stock. The current consensus rating on United Therapeutics Corporation (NASDAQ:UTHR) is Hold (Score: 2.33) with a consensus target price of…

New Post has been published on http://www.stockmarketsdaily.com/overvalued-stock-united-therapeutics-corporation-nasdaquthr/14837/

Overvalued Stock: United Therapeutics Corporation (NASDAQ:UTHR)

(adsbygoogle = window.adsbygoogle || []).push();

We look at United Therapeutics Corporation (NASDAQ:UTHR) a company in the Healthcare industry getting a lot of attention at the moment, to assess if it provides value for investors considering buying or selling it. Currently United Therapeutics Corporation is trading at $182.50 after moving down -0.65% in the previous day of trading. [Trend Analysis]

UTHR is trading with a trailing 12 month P/E multiple of 53.99 and an estimated forward P/E multiple of 15.14. The stock has an estimated 5 year annual growth of 19.56% and a PEG multiple of 2.76.

Rather than the usual Price to Earnings (P/E) multiple method, we use a slightly different method to assess if United Therapeutics Corporation is potentially a value buy for investors, the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the company rather than merely the growth for one earnings period ahead as forward P/E does.

That is to say, P/E simply doesn’t account for the long term prospects of UTHR. As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of UTHR being 2.76, we consider United Therapeutics Corporation to likely be overpriced.

This analysis means that value buyers who do not currently hold United Therapeutics Corporation (NASDAQ:UTHR) should not consider buying and investors currently holding the stock should consider selling.

New Post has been published on http://www.stockmarketsdaily.com/undervalued-buy-united-therapeutics-corporation-nasdaquthr/10490/

Undervalued Buy: United Therapeutics Corporation (NASDAQ:UTHR)

(adsbygoogle = window.adsbygoogle || []).push();

With United Therapeutics Corporation (NASDAQ:UTHR) [Trend Analysis] jumping up to new all time highs, we have a look to see if this price is justified from both a value and growth investor persepective by analyzing the current market consensus fundamentals for the stock.

United Therapeutics Corporation (NASDAQ:UTHR) last traded at $157.92 after moving up 1.78% for the trading day.

UTHR is trading with a trailing 12 month P/E multiple of 46.58 and an estimated forward P/E multiple of 15.99. The stock has an estimated 5 year annual growth of 27.63% and a PEG multiple of 1.69.

From a value investor perspective, as mentioned United Therapeutics Corporation trades on an estimated forward P/E multiple of 15.99. The current estimated forward P/E ratio for the market as a whole is approximately 19.82. Therefore, for value investors UTHR appears to be underpriced.

For growth investors, who are more interested in growth into the longer term for the stock, we look at the PEG multiple (P/E to growth) of United Therapeutics Corporation (NASDAQ:UTHR). This PEG multiple takes into account the expected long term growth in earnings of United Therapeutics Corporation rather than merely the growth for one full earnings period ahead.

As a rule of thumb, growth investors often believe a stock with a PEG of between 0 and 1 is considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced. Based on the PEG ratio of UTHR being 1.69, we consider United Therapeutics Corporation to likely be fairly priced.